ContraveExtended-Release (Orexigen Therapeutics, Inc.)
Welcome to the PulseAid listing for the Contrave drug offered from Orexigen Therapeutics, Inc.. This Opioid Antagonist [EPC],Opioid Antagonists [MoA],Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Orexigen Therapeutics, Inc. |
| NON-PROPRIETARY NAME: | naltrexone hydrochloride and bupropion hydrochloride |
| SUBSTANCE NAME: | NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Opioid Antagonist [EPC],Opioid Antagonists [MoA],Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, EXTENDED RELEASE |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2014-10-22 |
| END MARKETING DATE: | 0000-00-00 |
Contrave Extended-Release HUMAN PRESCRIPTION DRUG Details:
| Item Description | Contrave Extended-Release from Orexigen Therapeutics, Inc. |
| LABELER NAME: | Orexigen Therapeutics, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 8; 90(mg/1; mg/1) |
| START MARKETING DATE: | 2014-10-22 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 51267-890_4f565dd9-d6ee-4599-a974-a3eb24958d3d |
| PRODUCT NDC: | 51267-890 |
| APPLICATION NUMBER: | NDA200063 |
Other NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDE Pharmaceutical Manufacturers / Labelers:
